Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable inTrahepatic Cholangiocarcinoma (CORRECT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03898895
Recruitment Status : Recruiting
First Posted : April 2, 2019
Last Update Posted : December 10, 2019
Sponsor:
Information provided by (Responsible Party):
Ming Kuang, Sun Yat-sen University

Brief Summary:
The study is a multicenter phase II randomized trial. The purpose is to investigate both the efficacy and safety of radiotherapy combined with anti-PD-1 antibody and chemotherapy (gemcitabine+cisplatin) in unresectable intrahepatic cholangiocarcinoma patients.

Condition or disease Intervention/treatment Phase
Intrahepatic Cholangiocarcinoma Radiotherapy Immunotherapy Combination Product: Radiotherapy+anti-PD-1 Drug: Gemcitabine+cisplatin Phase 2

Detailed Description:
The trial will recruit 184 patients, and they will be randomized (1:1) into two groups (radiotherapy+anti-PD-1 group, gemcitabine+cisplatin group). Patients in radiotherapy+anti-PD-1 group will receive conventional intensity-modulated radiotherapy or stereotactic body radiation therapy first for a total dose more than 40Gy. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients in chemotherapy group will receive cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combination of Radiotherapy With Anti-PD-1 Antibody for Unresectable Intrahepatic Cholangiocarcinoma
Actual Study Start Date : December 1, 2019
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : November 2024


Arm Intervention/treatment
Experimental: Radiotherapy+anti-PD-1
The total radiation dose is over 40Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
Combination Product: Radiotherapy+anti-PD-1
The total radiation dose is over 40Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
Other Name: RA

Active Comparator: Gemcitabine+cisplatin
Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
Drug: Gemcitabine+cisplatin
Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
Other Name: GC




Primary Outcome Measures :
  1. Progression-free survival, PFS [ Time Frame: two years ]
    defined as the time from randomization until disease progression or death from any cause, whichever happens first. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and progression free. Patients not having an event will be censored at the date last seen alive.


Secondary Outcome Measures :
  1. Overall survival, OS [ Time Frame: two years ]
    defined as the time from randomization until death from any cause. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive. Patients remaining alive throughout the duration of the study will have their survival time censored on the date last seen alive.

  2. Adverse events, AE [ Time Frame: two years ]
    adverse events during the treatment period using Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).

  3. Tumor response [ Time Frame: two years ]
    measured according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 by means of computed tomography (CT) or magnetic resonance imaging (MRI) at each follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18-75 years;
  2. Primary unresectable ICC or recurrent unresectable ICC following curative therapies proved by pathology;
  3. No previous systemic chemotherapy or immunotherapy;
  4. The volume of normal liver is larger than 700ml, eligible for radiotherapy, chemotherapy and immunotherapy after evaluation of specialized experts;
  5. At least one measurable lesion based on RECIST 1.1 criteria;
  6. Child-Pugh A class;
  7. ECOG PS 0-1;
  8. Adequate hematologic, hepatic and renal function: ANC ≥ 1.5x10^9/L, Hb ≥ 90g/L, PLT ≥ 100 x10^9/L, albumin ≥ 28g/L, total bilirubin < 1.5×ULN at diagnosis or after biliary drainage, ALT and AST < 5×ULN, BUN、CREA<1.5×ULN, creatinine clearance rate ≥ 45ml/min;
  9. At least 12 weeks of life expectancy.

Exclusion Criteria:

  1. Have acute or chronic active hepatitis B or C, HBV-DNA>2000IU/ml or 104 copy/ml; HCV-RNA>103 copy/ml; both HBsAg and HCV antibody are positive. If the related results become lower than above standards after anti-viral treatment, the patients are qualified for enrolment;
  2. Have metastasis in extrahepatic distant organs including lung, central nervous system, bone and etc. Or extrahepatic lymph node metastasis beyond abdomen;
  3. Have risky bleeding events requiring transfusion, operation or local therapies, continuous medication in the past 3 months;
  4. Have thromboembolism in the past 6 months, including myocardial infarction, unstable angina, stroke or transient ischemic attack, pulmonary embolism, deep vein thrombosis;
  5. Have taken aspirin (>325mg/day) or other antiplatelet drugs continuously for 10 days or more within 2 weeks before enrolment;
  6. Uncontrollable hypertension, systolic pressure>140mmHg or diastolic pressure>90mmHg after best medical care, or history of hypertensive crisis or hypertensive encephalopathy;
  7. Symptomatic congestive heart failure (NYHA class II-IV). Symptomatic or badly-controlled arrhythmia. Congenital long QT syndrome or modified QTc>500ms upon screening;
  8. Have active autoimmune diseases that require systemic treatment within 2 years before enrolment;
  9. Active tuberculosis, having antituberculosis therapy at present or within 1 year;
  10. Have a known history of prior invasive malignancies within 5 years before enrolment;
  11. Pregnant or breastfeeding women, or expecting to conceive or father children within the projected duration of the trial;
  12. Have other uncontrollable comorbidities;
  13. Infection of HIV, known syphilis requiring treatment;
  14. Allergic to elements of camrelizumab, gemcitabine or cisplatin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03898895


Contacts
Layout table for location contacts
Contact: Ming Kuang, PhD 008687755766 ext 8576 kuangm@mail.sysu.edu.cn

Locations
Layout table for location information
China, Guangdong
The First Affiliated Hospital of Sun Yat-sen University Recruiting
Guangzhou, Guangdong, China, 510080
Contact: Ming Kuang, Ph.D.    008687755766 ext 8576    kuangm@mail.sysu.edu.cn   
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Layout table for investigator information
Study Chair: Ming Kuang, PhD First Affiliated Hospital, Sun Yat-Sen University
Layout table for additonal information
Responsible Party: Ming Kuang, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03898895    
Other Study ID Numbers: ICC001
First Posted: April 2, 2019    Key Record Dates
Last Update Posted: December 10, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangiocarcinoma
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Gemcitabine
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs